Therefore, cell-based TIMP3 delivery could be an efficient approach for MI since TIMP3 can inhibit metalloproteinases and activation of TNF-α, as well as promote angiogenesis, and further improve the structure and function of the heart post-MI. The gene discussed is TIMP3; the disease is myocardial infarction.